SCHEMBL347441

SCHEMBL347441

Brc1ccc(-c2ccc(Oc3ccc(-n4c5ccccc5c5ccccc54)cc3)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.48
ATM Q13315 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
HDAC4 P56524 1/20 0.43
PTPN1 P18031 1/20 0.41
ALDH1A1 P00352 2/20 0.39
MAPK1 P28482 1/20 0.39
ABCG2 Q9UNQ0 1/20 0.39
MAPT P10636 2/20 0.39
MCL1 Q07820 2/20 0.38
SCN9A Q15858 3/20 0.37
HTT P42858 2/20 0.37
TSHR P16473 1/20 0.37
LTA4H P09960 1/20 0.36
NTRK1 P04629 1/20 0.36
IGF1R P08069 1/20 0.36
FGFR1 P11362 1/20 0.36
NTRK3 Q16288 1/20 0.36
NTRK2 Q16620 1/20 0.36
LMNA P02545 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16125388 0.92 KDM4E (0.57) KDM4EATML3MBTL1HDAC4PTPN1
SCHEMBL29581819 0.90 KDM4E (0.59) KDM4EATML3MBTL1HDAC4PTPN1
SCHEMBL17742560 0.90 KDM4E (0.59) KDM4EATML3MBTL1HDAC4PTPN1
SCHEMBL347580 0.90 KDM4E (0.59) KDM4EATML3MBTL1HDAC4PTPN1
SCHEMBL4570440 0.86 KDM4E (0.64) KDM4EATML3MBTL1PTPN1ALDH1A1
SCHEMBL13049621 0.86 KDM4E (0.64) KDM4EATML3MBTL1PTPN1ALDH1A1
SCHEMBL29400116 0.84 KDM4E (0.67) KDM4EATML3MBTL1HDAC4PTPN1
SCHEMBL262160 0.84 KDM4E (0.67) KDM4EATML3MBTL1HDAC4PTPN1
SCHEMBL3904085 0.83 KDM4E (0.65) KDM4EATML3MBTL1PTPN1SCN9A
SCHEMBL16890387 0.83 KDM4E (0.52) KDM4EATML3MBTL1HDAC4PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2448925-B1 EMISSIVE ARYL-HETEROARYL COMPOUNDS NITTO DENKO CORP (JP) 2017-12-06 EP disclosed
EP-2448925-B1 EMISSIVE ARYL-HETEROARYL COMPOUNDS NITTO DENKO CORP (JP) 2017-12-06 EP disclosed
US-8927121-B2 Emissive aryl-heteroaryl compounds NITTO DENKO CORPORATION (JP) 2015-01-06 US disclosed
US-8927121-B2 Emissive aryl-heteroaryl compounds NITTO DENKO CORPORATION (JP) 2015-01-06 US disclosed
US-8927121-B2 Emissive aryl-heteroaryl compounds NITTO DENKO CORPORATION (JP) 2015-01-06 US disclosed
US-8771845-B2 2014-07-08 US disclosed
US-8771845-B2 2014-07-08 US disclosed
US-8771845-B2 2014-07-08 US disclosed
US-20130284907-A1 EMISSIVE ARYL-HETEROARYL COMPOUNDS NITTO DENKO CORPORATION (JP) 2013-10-31 US disclosed
US-20130284907-A1 EMISSIVE ARYL-HETEROARYL COMPOUNDS NITTO DENKO CORPORATION (JP) 2013-10-31 US disclosed
US-20120015998-A1 PHOTOTHERAPY METHODS AND DEVICES COMPRISING EMISSIVE ARYL-HETEROARYL COMPOUNDS NITTO DENKO CORPORATION (JP) 2012-01-19 US disclosed
US-20120015998-A1 PHOTOTHERAPY METHODS AND DEVICES COMPRISING EMISSIVE ARYL-HETEROARYL COMPOUNDS NITTO DENKO CORPORATION (JP) 2012-01-19 US disclosed
US-20120015998-A1 PHOTOTHERAPY METHODS AND DEVICES COMPRISING EMISSIVE ARYL-HETEROARYL COMPOUNDS NITTO DENKO CORPORATION (JP) 2012-01-19 US disclosed
WO-2012009283-A1 PHOTOTHERAPY METHODS AND DEVICES COMPRISING EMISSIVE ARYL-HETEROARYL COMPOUNDS NITTO DENKO CORPORATION (JP) 2012-01-19 WO disclosed
WO-2012009283-A1 PHOTOTHERAPY METHODS AND DEVICES COMPRISING EMISSIVE ARYL-HETEROARYL COMPOUNDS NITTO DENKO CORPORATION (JP) 2012-01-19 WO disclosed
WO-2011008560-A1 EMISSIVE ARYL-HETEROARYL COMPOUNDS NITTO DENKO CORPORATION (JP) 2011-01-20 WO disclosed
WO-2011008560-A1 EMISSIVE ARYL-HETEROARYL COMPOUNDS NITTO DENKO CORPORATION (JP) 2011-01-20 WO disclosed
US-20100326526-A1 EMISSIVE ARYL-HETEROARYL COMPOUNDS NITTO DENKO CORPORATION (JP) 2010-12-30 US disclosed
US-20100326526-A1 EMISSIVE ARYL-HETEROARYL COMPOUNDS NITTO DENKO CORPORATION (JP) 2010-12-30 US disclosed
US-20100326526-A1 EMISSIVE ARYL-HETEROARYL COMPOUNDS NITTO DENKO CORPORATION (JP) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015998-A1 PHOTOTHERAPY METHODS AND DEVICES COMPRISING EMISSIVE ARYL-HETEROARYL COMPOUNDS ARNT, AHR, AR KDM4E 3036/4885ATM 1351/4885L3MBTL1 2273/4885
US-20100326526-A1 EMISSIVE ARYL-HETEROARYL COMPOUNDS AHR, AR, ARNT KDM4E 3441/4885ATM 2026/4885L3MBTL1 3255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.